Cover Image

Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study

Heart failure (CHF) guidelines recommend mineralocorticoid receptor antagonists for all symptomatic patients treated with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers. As opposed to both eplerenone trials, patients in RALES (spironolactone) received almost n...

Full description

Saved in:
Bibliographic Details
Main Authors: Frankenstein, Lutz (Author) , Katus, Hugo (Author) , Grundtvig, M. (Author) , Hole, T. (Author) , de Blois, J. (Author) , Schellberg, Dieter (Author) , Atar, D. (Author) , Zugck, Christian (Author) , Agewall, S. (Author)
Format: Article (Journal)
Language:English
Published: 07 June 2013
In: European journal of clinical pharmacology
Year: 2013, Volume: 69, Issue: 10, Pages: 1747-1755
ISSN:1432-1041
DOI:10.1007/s00228-013-1512-x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00228-013-1512-x
Get full text
Author Notes:L. Frankenstein, H.A. Katus, M. Grundtvig, T. Hole, J. de Blois, D. Schellberg, D. Atar, C. Zugck, S. Agewall, on behalf of the Norwegian Heart Failure Registry steering committee
Description
Summary:Heart failure (CHF) guidelines recommend mineralocorticoid receptor antagonists for all symptomatic patients treated with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers. As opposed to both eplerenone trials, patients in RALES (spironolactone) received almost no beta-blockers. Since pharmacological properties differ between eplerenone and spironolactone, the prognostic benefit of spironolactone added to this baseline combination therapy needs clarification.
Item Description:Gesehen am 30.04.2021
Physical Description:Online Resource
ISSN:1432-1041
DOI:10.1007/s00228-013-1512-x

Similar Items